Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | CPN1 | P15169 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109055 | 0.88 | CPN1 (0.40) | DPP4DPP7DPP8DPP9CPN1 | |
| SCHEMBL20756331 | 0.83 | CHRNB2 (0.38) | CPN1CPB2ALOX5 | |
| SCHEMBL15837592 | 0.82 | PIK3CD (0.38) | DPP4DPP7DPP8DPP9CPN1 | |
| SCHEMBL15837591 | 0.82 | PIK3CD (0.38) | DPP4DPP7DPP8DPP9CPN1 | |
| SCHEMBL679537 | 0.82 | PIK3CD (0.38) | DPP4DPP7DPP8DPP9CPN1 | |
| SCHEMBL13035374 | 0.82 | CPN1 (0.38) | DPP4DPP7DPP8DPP9CPN1 | |
| SCHEMBL25961563 | 0.80 | DPP4 (0.41) | DPP4DPP7DPP8DPP9CPN1 | |
| SCHEMBL16999004 | 0.80 | CHRNB2 (0.46) | DPP4DPP7DPP8DPP9MEN1 | |
| SCHEMBL10232854 | 0.80 | CPN1 (0.37) | DPP4DPP7DPP8DPP9CPN1 | |
| SCHEMBL18074021 | 0.80 | CHRNB2 (0.46) | DPP4DPP7DPP8DPP9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-109096274-B | Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases | 比奥根MA公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-109096274-A | It can be used for treating the aryl-linking compound of human tumor, neurology and amynologic disease | 比奥根MA公司 | 2018-12-28 | — | — | CN | disclosed |
| CN-108947913-A | It can be used for treating the aryl-linking compound of human tumor, neurology and amynologic disease | 比奥根MA公司 | 2018-12-07 | — | — | CN | disclosed |
| CN-106459002-B | Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases | 比奥根MA公司 | 2018-08-21 | — | — | CN | disclosed |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
| CN-106459002-A | Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases | 比奥根MA公司 | 2017-02-22 | — | — | CN | disclosed |
| US-8188085-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | DPP4 3912/4885DPP7 2870/4885DPP8 2863/4885 |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | DPP4 3722/4885DPP7 2591/4885DPP8 3155/4885 |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | DPP4 1075/4885DPP7 846/4885DPP8 610/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | DPP4 1075/4885DPP7 846/4885DPP8 610/4885 |
| US-20100113439-A1 | Antifungal agents | GMDS, GBA3, UGGT1 | DPP4 221/4885DPP7 187/4885DPP8 179/4885 |
| US-11814384-B2 | Inhibtors of Raf kinases | RAF1, BRAF, ARAF | DPP4 4369/4885DPP7 3284/4885DPP8 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.